This study examined the effectiveness of tirzepatide in commercially insured individuals without diabetes who were eligible for obesity medications. The research utilized data from Optum’s Market Clarity database, focusing on adults with continuous enrollment and documented tirzepatide prescriptions between November 2023 and March 2024. The study included two cohorts: individuals who had not previously used glucagon like-peptide-1 receptor agonists (GLP-1 RA) and those who had.
Data was collected from 353 individuals, comprising 230 GLP-1 RA-naïve individuals and 123 GLP-1 RA-experienced individuals, who remained on tirzepatide for 12 months. Baseline assessments revealed that a majority of participants had at least one obesity-related complication, frequently dyslipidemia, hypertension, and prediabetes.
At the 12-month mark, the GLP-1 RA-naïve cohort demonstrated a mean weight reduction of 19.3%, while the GLP-1 RA-experienced cohort achieved a mean weight reduction of 13.1%.
These real-world findings indicated clinically meaningful weight reduction with persistent tirzepatide use, mirroring outcomes observed in clinical trials, across both GLP-1 RA-naïve and experienced populations.